Paramount Bio Sciences, LLC, a global pharmaceutical advancement and well being care expenditure company, was launched and managed by Dr. Lindsay A. Rosenwald in 1991. The business facilitates drug development, scientific support and dedicates alone to getting and producing novel therapeutic medicines with massive probable. By evaluating promising drug candidates around the world, Paramount has been equipped to develop, nurture, and assistance far more than 40 lifetime sciences businesses, educational centers, biotechnology and pharmaceutical firms above the earlier 19 many years, together with 20 in the very last 48 months. Present-day Portfolio Corporations have more than 40 solution candidates advancing through medical trials.
Special tactic to bio tech investment decision
Enterprise and product or service enhancement are just two items in the Paramount puzzle. An affiliate of Paramount Bio Sciences – Paramount Bio Funds, Inc., is a FINRA registered broker-supplier that, among the other activities, raises money for the Paramount Portfolio Corporations. It raised over $1 billion for the Portfolio Organizations numerous situations that amount has been raised for Paramount Corporations by other entities. Even though enterprise money and non-public fairness companies are inclined to be financial commitment-oriented, Paramount’s bias is on the operational facet. It establishes companies from the ground up, making use of its personal capital and at some point resources lifted from various personal and institutional investors by means of Paramount Bio Sciences and other banks and broker-dealers on Wall Road. Absolutely, Paramount’s expertise in finance and small business locations aids make the product desirable to probable licensors and main govt officers.
With Paramount Capital largely handling accounting, financial, sector analytical and authorized capabilities, administrators of its Portfolio Providers can emphasis mainly on driving drug candidates by way of the clinic and building worth for shareholders, licensors and the client neighborhood.
Infrastructure and Business Creating at Paramount
Paramount involves an considerable assist infrastructure with practical experience in licensing, clinical advancement, corporate functions, and navigating regulatory pathways. Each individual new portfolio corporation at Paramount Bio Sciences is built all over intriguing science and business possible. The Portfolio Firms are operated by Paramount Cash as a result of a focused very first-class administration at the corporation level, as nicely as by means of organization and medical enhancement and operations specialists working for Paramount in New York. Chelsea Therapeutics, for example, to begin with was produced or launched by Dr. Rosenwald around a novel anti-folate becoming designed for the procedure of inflammatory situations that incorporated rheumatoid arthritis (RA) and psoriasis. Chelsea’s compound, CH-1504, has demonstrated superiority in phrases of both security and efficacy more than Methotrexate, the existing cure common for RA, which has been uncovered to elevate liver enzymes in quite a few sufferers. Paramount Capital licensed this engineering from the University of South Alabama and assembled a entire world-course management staff to assistance optimize its formulation and progress the growth of this and other compounds.
Another educational license from Paramount is a portfolio of natural and organic arsenic trioxide compounds licensed from the MD Anderson Cancer Center. This Fda accepted compound progressed from IND to NDA in about 30 months and this is the swiftest regulatory acceptance in the Fda history. Trisenox, an inorganic alternative of arsenic trioxide, which can products provides cardiac abnor¬malities at higher doses. By distinction with the inorganic edition, natural arsenic trioxide does not demonstrate evidence of these challenges, even when applied at doses 20 occasions larger than Trisenox. To leverage that edge, Dr. Rosenwald founded Ziopharm Oncology to progress this natural and organic arsenic compound, ZIO-101, to deal with cancers, which includes solid tumors, in which mega dosing has established effective. Ziopharm Oncology, as one particular of numerous Paramount’s portfolio firms, subsequently has in-certified and is establishing various other anti-most cancers agents.
Another Paramount portfolio enterprise, started and managed by Lindsay Rosenwald M.D., is Keryx Bio pharmaceuticals. It is establishing a compound termed Sulonex, which is an oral therapy for diabetic nephropathy. It was licensed from the Alfa Wassermann Team, a privately held pharmaceutical company in Bologna, Italy. If accredited, Sulonex will be promoted to 15 million folks identified with Kind 2 diabetic issues as effectively as the 1 to 2 million sufferers with Variety 1 diabetic issues.